drug
elinzanetant
Marketedupdated 5mo agoby Bayer USA LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
Trials studying elinzanetant
- phase3A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
- phase3A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
- phase3A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
- phase3A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
- phase2A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
- phase1A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally
- phase1A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women
- phase1A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 24, 2030
~4.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- May 14, 2045method-of-use (U-4402)US 12533358
- Mar 13, 2039formulationUS 10774091
- Mar 13, 2039method-of-use (U-3622)US 11787820
- Mar 13, 2039method-of-use (U-3622)US 12264164
- May 18, 2036method-of-use (U-3622)US 10195205
- Sep 15, 2026compositionUS 7683056
FDA exclusivities (1)
- Oct 24, 2030NCENew Chemical Entity (5y)4.1y
News(3)
- Will a ‘reset’ reignite investment in women’s health startups?After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI and a widening definition of what constitutes women’s health could spur…biopharma_dive · 1mo ago
- AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashesAbCellera Biologics’ reduction in hot flashes sets it apart from currently commercial oral drugs, including Astellas’ Veozah and Bayer’s Lynkuet, according to BMO Capital Markets.biospace · 1mo ago
- AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on noticeAbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women…fiercebiotech · 1mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that